HCMT
TVTX icon

Highland Capital Management (Tennessee)’s Travere Therapeutics TVTX Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$494K Buy
+8,701
New +$386K 0.02% 314

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Highland Capital Management (Tennessee)'s TVTX Position: Q2 2026 in Review

Highland Capital Management (Tennessee) opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 8,701 shares worth $494K. The stake represents 0.02% of the portfolio and ranks #314 among its holdings.

121 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Highland Capital Management (Tennessee) held 8,701 shares of Travere Therapeutics worth $494K as of Q2 2026.
  • Travere Therapeutics was a new Highland Capital Management (Tennessee) position in Q2 2026.
  • Travere Therapeutics made up 0.02% of Highland Capital Management (Tennessee)'s portfolio in Q2 2026, its #314 holding.
  • 121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q2 2026, filed 21 Jul 2026.